Document:

exv4w1

Exhibit 4.1

THIS TERM LOAN PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS TERM LOAN PROMISSORY NOTE
MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT FOR THE TERM LOAN PROMISSORY NOTE UNDER APPLICABLE SECURITIES
LAWS OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.

THE RIGHT OF THE HOLDER OF THIS TERM LOAN PROMISSORY NOTE TO RECEIVE PAYMENT HEREUNDER IS
SUBORDINATED IN PAYMENT TO THE SENIOR DEBT TO THE EXTENT AND IN THE MANNER SET FORTH IN SECTION 8
OF THIS TERM LOAN PROMISSORY NOTE.

TERM LOAN PROMISSORY NOTE

			
	 	 	 
	$15,000,000.00
	 	June 1, 2010

          FOR VALUE RECEIVED, COLUMBIA LABORATORIES, INC., a Delaware corporation (“Borrower”),
promises to pay WATSON PHARMACEUTICALS, INC., a Nevada corporation (which, together with its
permitted assigns, is referred to in this Note as “Lender”) at 311 Bonnie Circle, Corona,
California 92880, or such other place as Lender may from time to time designate, the principal sum
of Fifteen Million and 00/100 Dollars ($15,000,000.00), together with interest on unpaid principal
from the date hereof at the rate of four percent (4.00%) per annum, or as otherwise provided
herein, with principal and interest payable in the manner provided below in lawful money of the
United States. All amounts due under this Note shall be payable without defense, set off or
counterclaim.

     1. Certain Defined Terms. As used in this Note, the following terms shall have the
meanings hereinafter set forth:

          1.1 “Affiliate” shall mean, with respect to any Person (as defined below), any other
Person controlling, controlled by or under direct or indirect common control with such Person (for
the purposes of this definition “control,” when used with respect to any specified Person,
shall mean the power to direct the management and policies of such Person, directly or indirectly,
whether through ownership of voting securities, by contract or otherwise; and the terms
“controlling” and “controlled” shall have meanings correlative to the foregoing).

          1.2 “Common Stock” shall mean the common stock, par value $0.01 per share, of
Borrower.

          1.3 “Convertible Notes” shall mean the “Notes” issued pursuant to that certain
Securities Purchase Agreement dated as of December 21, 2006, by and among Borrower and the
“Purchasers” party thereto, as the same may be amended or modified from time to time in
accordance with the terms thereof.

 

 

          1.4 “Convertible Notes Debt” shall mean all amounts (including all principal,
interest, premiums and other payments) payable by Borrower under the Convertible Notes.

          1.5 “Default” shall have the meaning provided in Section 4 below.

          1.6 “Default Interest” shall have the meaning provided in Section 5 below.

          1.7 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

          1.8 “Fundamental Transaction” shall mean that (a) Borrower shall, directly or
indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or
not Borrower is the surviving corporation) another Person or Persons, or (ii) sell, assign,
transfer, convey or otherwise dispose of all or substantially all of the properties or assets of
Borrower to another Person, or (iii) allow another Person to make a purchase, tender or exchange
offer that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock
(not including any shares of Voting Stock held by the Person or Persons making or party to, or
associated or affiliated with the Persons making or party to, such purchase, tender or exchange
offer), or (iv) consummate a stock purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than the 50% of the outstanding shares of
Voting Stock (not including any shares of Voting Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such
stock purchase agreement or other business combination), or (v) reorganize, recapitalize or
reclassify its Common Stock, or (b) any “person” or “group” (as these terms are used for purposes
of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner” (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate
Voting Stock of Borrower. Notwithstanding anything to the contrary contained in the foregoing, a
“Fundamental Transaction” as defined in this Note will not include the transactions among Borrower
and Watson Pharmaceuticals, Inc. and/or Watson Pharmaceuticals, Inc.’s Affiliates contemplated by
the Purchase Agreement.

          1.9 “Indebtedness” of any Person shall mean, without duplication (a) all indebtedness
for borrowed money, (b) all obligations issued, undertaken or assumed as the deferred purchase
price of property or services, including (without limitation) “capital leases” in accordance with
generally accepted accounting principles as in effect in the United States (“GAAP”) (other
than trade payables entered into in the ordinary course of business), (c) all reimbursement or
payment obligations with respect to letters of credit, surety bonds and other similar instruments,
(d) all obligations evidenced by notes, bonds, debentures or similar instruments, including
obligations so evidenced incurred in connection with the acquisition of property, assets or
businesses, (e) all indebtedness created or arising under any conditional sale or other title
retention agreement, or incurred as financing, in either case with respect to any property or
assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the
seller or bank under such agreement in the event of default are limited to repossession or sale of
such property), (f) all monetary obligations under any leasing or similar
arrangement which, in connection with GAAP, consistently applied for the periods covered
thereby, is classified as a capital lease, (g) all indebtedness referred to in clauses (a) through
(f)

2

 

above secured by (or for which the holder of such Indebtedness has an existing right,
contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or
other encumbrance upon or in any property or assets (including accounts and contract rights) owned
by any Person, even though the Person which owns such assets or property has not assumed or become
liable for the payment of such indebtedness, and (h) all contingent obligations in respect of
indebtedness or obligations of others of the kinds referred to in clauses (a) through (g) above.

          1.10 “Material Adverse Effect” shall mean a material adverse effect on the business,
properties, assets, operations, results of operations or financial condition of Borrower and its
subsidiaries, taken as a whole, or on the authority or ability of Borrower to perform its
obligations hereunder.

          1.11 “Payment Suspension Period” shall have the meaning provided in Section 8 below.

          1.12 “Permitted Indebtedness” of any Person means (i) all Indebtedness of a type set
forth in clause (b) of the definition of Indebtedness, (ii) all Indebtedness of a type set forth in
clause (c) of the definition of Indebtedness and incurred in the ordinary course of business, and
(iii) unsecured Indebtedness between Borrower and any of its subsidiaries or between its
subsidiaries.

          1.13 “Person” shall mean any person, individual, corporation, limited liability
company, partnership, trust or other nongovernmental entity or any governmental agency, court,
authority or other body (whether foreign, federal, state, local or otherwise).

          1.14 “PharmaBio Debt” shall mean all amounts payable by Borrower to PharmaBio (as
defined below) under the 2003 Investment and Royalty Agreement (as defined below), including (i)
the total royalties payable by Borrower to PharmaBio Development Inc., a North Carolina corporation
(“PharmaBio”) pursuant to Section 2.3 of that certain Investment and Royalty Agreement
dated March 5, 2003, by and between Borrower and PharmaBio, as amended by the Letter Agreement
dated January 26, 2004, supplemented by the Letter Agreement dated April 14, 2006, amended by the
Letter Agreement dated July 22, 2009 and amended by the Letter Agreement dated March 3, 2010
(collectively, the “2003 Investment and Royalty Agreement”) up to an aggregate amount of
$30,000,000, and (ii) the Repayment Amount (as defined in the 2003 Investment and Royalty
Agreement), if any, owing by Borrower to PharmaBio pursuant to Section 2.2 of the 2003 Investment
and Royalty Agreement.

          1.15 “Purchase Agreement” shall mean that certain Purchase and Collaboration Agreement
dated as of March 3, 2010 among Borrower, Lender and Coventry Acquisition, Inc., as the same may be
amended, restated, supplemented or otherwise modified from time to time in accordance with its
terms.

          1.16 “Required Repayment Date” shall mean the earliest to occur of: (a) the Scheduled
Maturity Date, (b) after the occurrence of a Fundamental Transaction, the earlier of (i) the date
upon which all of the Convertible Notes Debt has been paid in full or (ii) 21 Trading
Days (as defined in the Convertible Notes) after the occurrence of such Fundamental
Transaction, or (c) the acceleration of all amounts due hereunder pursuant to Section 4 hereof.

3

 

          1.17 “Scheduled Maturity Date” shall mean December 31, 2011.

          1.18 “Senior Debt” shall mean each of (a) the PharmaBio Debt and (b) the Convertible
Notes Debt.

          1.19 “Senior Debt Documents” shall mean all agreements, documents and instruments
entered into by or binding on the Borrower in connection with any of the Senior Debt.

          1.20 “Senior Default” shall mean (a) the occurrence and continuance (after any
applicable grace period) of a default in payment of all or any part of any Senior Debt, (b) the
occurrence and continuance (after any applicable grace period) of any other default of the terms
and conditions of any Senior Debt (other than a default under any Convertible Note that is
described in the clause (c)) if the effect of such default is (1) to cause all or any portion of
any Senior Debt to become due prior to its stated maturity or (2) to permit any holder of all or
any portion of any Senior Debt to cause such Senior Debt to become due prior to its stated
maturity; provided, that, any Senior Default described in clause (b)(2) arising as a result of a
default under any of the Convertible Notes shall expire if and when the applicable holder does not
exercise its right to cause such Senior Debt to become due within 35 days after it obtains
knowledge of such default; or (c) the occurrence of any event that provides any holder of any
Convertible Notes with cash redemption rights prior to the stated maturity of such Convertible
Notes; provided, that, in the case of clause (c), the holders thereof have exercised such
redemption rights within the time period provided in Section 5(e)(ii) of the Convertible Notes.

          1.21 “Subordinated Debt” shall have the meaning provided in Section 8.1 below.

          1.22 “Voting Stock” of a Person shall mean the capital stock of such Person of the
class or classes pursuant to which the holders thereof have the general voting power to elect, or
the general power to appoint, at least a majority of the board of directors, managers or trustees
of such Person (irrespective of whether or not at the time capital stock of any other class or
classes shall have or might have voting power by reason of the happening of any contingency).

     2. Payment of Principal and Interest. Principal of and interest under this Note shall
be payable as follows:

          2.1 Required Repayment. Subject to Section 2.3, the entire unpaid principal balance
of this Note and all accrued and unpaid interest under this Note shall be due and payable on the
Required Repayment Date. Borrower acknowledges that a balloon payment of principal and accrued
interest shall be payable on the Required Repayment Date.

          2.2 Calculation of Interest. Interest payable with respect to any period shall be
calculated according to the actual number of days in such period as a fraction of a three hundred
sixty (360) day year.

          2.3 Forgiveness upon First Closing under Purchase Agreement. Notwithstanding anything
to the contrary in this Note or elsewhere, upon the occurrence of the First Closing (as defined in
the Purchase Agreement) in accordance with the Purchase

4

 

Agreement, all amounts otherwise due and
payable under or in respect of this Note shall be deemed forgiven in full automatically and without
need of further action by any Person, and Lender shall, if so requested by Borrower, mark this Note
cancelled and return the same to Borrower.

     3. No Voluntary Prepayment; Prepayment Fee. Borrower shall have no right to
voluntarily prepay the principal amount outstanding under this Note in whole or in part at any time
prior to the Scheduled Maturity Date. Notwithstanding anything to the contrary in this Note, if
the Required Repayment Date occurs by reason of the occurrence of a Fundamental Transaction prior
to August 31, 2011, then Borrower shall pay to Lender on the Required Repayment Date, in addition
to all other amounts due and payable hereunder, a prepayment fee in the amount of Two Million
Dollars ($2,000,000.00).

     4. Default; Acceleration. Upon and for so long as any one or more of the following
events shall be continuing (each a “Default”):

          (a) Payments. Borrower shall fail to make any payment required hereunder on or before
the date such payment is due;

          (b) Representations and Warranties. Any representation or warranty made by Borrower
in this Note shall prove to have been untrue, incorrect or misleading in any material respect when
made;

          (c) Additional Indebtedness. Borrower shall fail duly to observe the covenants
contained in Section 10 of this Note;

          (d) Other Covenants. Borrower shall fail duly to observe or perform any covenant or
agreement contained in this Note (other than a failure referred to in paragraph (a) or (c) of this
Section 4) and such failure shall continue unremedied for a period of 30 days following Borrower’s
knowledge thereof;

          (e) Cross Defaults. Borrower or any subsidiary of Borrower defaults in the
performance of any obligation if the effect of such default is to cause an amount exceeding
$500,000 to become due prior to its stated maturity or to permit the holder or holders of such
obligation to cause an amount exceeding $500,000 to become due prior to its stated maturity;

          (f) Judgment Liens. A judgment, to the extent not covered under an insurance policy,
in excess of $1,000,000 is rendered against Borrower and, within 60 days after entry thereof, such
judgment is not discharged in full or execution thereof stayed pending appeal, or within 60 days
after the expiration of any such stay, such judgment is not discharged in full; or

          (g) Insolvency. Borrower makes an assignment for the benefit of creditors or admits
in writing its inability to pay its debts generally as they become due; or an order, judgment or
decree is entered adjudicating Borrower bankrupt or insolvent; or any order for relief with respect
to Borrower is entered under the federal bankruptcy code; or Borrower petitions or applies to any
tribunal for the appointment of a custodian, trustee, receiver or liquidator of Borrower, or of any
substantial part of the assets of Borrower, or commences any proceeding relating to Borrower under
any bankruptcy reorganization, arrangement, insolvency,

5

 

readjustment of debt, dissolution or
liquidation law of any jurisdiction; or any such petition or application is filed, or any such
proceeding is commenced, against Borrower and either (i) Borrower by any act indicates its approval
thereof, consents thereto or acquiesces therein or (ii) such petition, application or proceeding is
not dismissed within 60 days;

then, on notice of acceleration by Lender to Borrower in the case of a Default specified in
subsections (a) through (f) above, or automatically and immediately without demand, notice, protest
or other action of any kind by Lender, which Borrower hereby expressly waives, in the case of any
Default specified in subsection (g) above, all amounts outstanding under this Note shall, subject
to the provisions of Section 8 hereof, be immediately due and payable in full.

     5. Late Payment Charge; Default Interest. If any payment under this Note (whether of
principal, interest, prepayment fee or other, and including the payment due on the Required Payment
Date or upon any acceleration of this Note) is not paid within five (5) days after the due date
thereof, Borrower shall pay to Lender, in addition to the delinquent payment and without any
requirement of notice or demand by Lender, a late payment charge equal to five percent (5%) of the
amount of the delinquent payment. In addition, upon the occurrence of a Default and so long as the
same shall remain uncured, all unpaid amounts hereunder, together with all accrued but unpaid
interest thereon, shall, from and after such Default, bear interest at the rate of nine percent
(9.00%) per annum (the “Default Rate”), instead of four percent (4.00%) per annum.
BORROWER ACKNOWLEDGES AND AGREES THAT (i) LENDER’S ACTUAL DAMAGES RESULTING FROM ANY SUCH DEFAULT
OR DELINQUENCY AND THAT RELATE TO LOST USE OF FUNDS OR COSTS OF INTERNAL ADMINISTRATION OF
DELINQUENT PAYMENTS HEREUNDER OR RELATING TO SUCH DEFAULT WOULD BE EXTREMELY DIFFICULT TO
ASCERTAIN, AND (ii) UNDER THE CIRCUMSTANCES IN EXISTENCE AS OF THE DATE HEREOF, INTEREST HEREUNDER
ACCRUED AT THE DEFAULT RATE AND SUCH LATE CHARGES CONSTITUTE A REASONABLE LIQUIDATION OF SUCH
DAMAGES. No provision in this Note (including without limitation the provisions for a late payment
charge, accrual of interest at any increased rate on and after the occurrence of a Default, or for
the continued accrual of interest on any amounts remaining unpaid after the Required Payment Date)
shall be construed as in any way excusing Borrower from its obligation to make each payment under
this Note promptly when due.

     6. Costs of Collection. Borrower and all endorsers hereof jointly and severally
promise to pay (a) all costs and expenses, including without limitation actual attorneys’ fees, if
this Note or any portion of this Note is placed in the hands of any attorney for collection and
such collection is effected
without suit; (b) attorneys’ fees, as determined by the judge of the court, and all other
costs, expenses and fees incurred by Lender in enforcing its rights under this Note; including,
without limitation, the institution of a suit to collect all or any portion of amounts owing under
this Note; and (c) all costs and expenses, including without limitation, actual attorneys’ fees,
incurred by Lender in connection with any bankruptcy, insolvency or reorganization proceeding or
receivership involving Borrower, including without limitation attorneys’ fees incurred in making
any appearances in any such proceeding or in seeking relief from any stay or injunction issued in
or arising out of any such proceeding.

6

 

     7. Certain Waivers. Borrower waives diligence, grace, demand, presentment for
payment, exhibition of this Note, protest, notice of nonpayment, and any and all exemption rights
against the indebtedness evidenced by this Note. From time to time, without affecting the
obligation of Borrower or the successors or assigns of Borrower to pay the outstanding principal
balance of this Note and observe the covenants of Borrower contained herein, without giving notice
to or obtaining the consent of Borrower, the successors or assigns of Borrower, and without
liability on the part of Lender, Lender may, at the option of Lender, extend the time for payment
of said outstanding principal balance, or any part thereof, release anyone liable on any of said
outstanding principal balance, accept a renewal of this Note, join in any extension or
subordination agreement, and agree in writing with Borrower to modify the rate of interest of this
Note.

          No single or partial exercise of any power hereunder shall preclude other and further exercise
thereof or the exercise of any other power. No delay or omission on the part of Lender in
exercising any right hereunder shall operate as a waiver of such right or of any other right
hereunder.

     8. Subordination.

          8.1 Extent of Subordination. All amounts (including all principal, interest,
fees/premiums and other payments) payable under this Note (the “Subordinated Debt”) are and
shall be subordinate and junior in right of payment to the prior payment in full of the Senior Debt
to the extent and in the manner set forth in this Section 8. Each holder of the Senior Debt, or any
portion thereof, whether now outstanding or hereafter incurred, shall be deemed to have acquired
the Senior Debt in reliance upon the provisions contained in this Section 8. This Section 8 shall
constitute a continuing offer to all Persons who become holders of, or continue to hold, the Senior
Debt, and the provisions herein are made for the benefit of the holders of the Senior Debt, and
such holders are made obligees hereunder and any one or more of them may enforce such provisions.

          8.2 Payment Suspension. Lender shall, at all times, be entitled to receive payments
on account of the Subordinated Debt in accordance with the terms of this Note; provided, however,
that, if and so
long as any Senior Default has occurred and is continuing, and Lender has received a copy of
written notice thereof (the “Senior Default Notice”) that has been furnished to Borrower by
any holder of Senior Debt (such period of time being referred to as the “Payment Suspension
Period”), then, except as otherwise set forth below, Borrower shall not make, and the holders
of the Subordinated Debt shall not accept or receive from Borrower, directly or indirectly, in cash
or other property or by set-off or in any other manner (including, without limitation, from or by
way of any collateral or redemption or sale), payment of all or any part of the Subordinated Debt
unless and until the earlier of (i) the Senior Debt then subject to the Senior Default has been
paid in full or (ii) such Senior Default has been cured by Borrower or waived by such holders of
such Senior Debt then subject to the Senior Default or such holders of the outstanding principal
amount of such Senior Debt then subject to the Senior Default have terminated the Payment
Suspension Period, in each case in accordance with the terms of the relevant agreements governing
such Senior Debt.

7

 

          8.3 Liquidation, Winding Up, etc. Upon any distribution of assets of Borrower or upon
any dissolution, winding up, liquidation or reorganization of Borrower, whether in any bankruptcy,
insolvency, reorganization or receivership proceeding or upon an assignment for the benefit of
creditors or any other marshalling of the assets and liabilities of Borrower:

               (a) the holders of all Senior Debt shall be entitled to receive payment in full of the
principal thereof, the interest due thereon and any premium or other payment obligation with
respect thereto before the holders of the Subordinated Debt are entitled to receive any payment
upon the Subordinated Debt; and

               (b) any payment or distribution of assets of Borrower of any kind or character, whether in
cash, property or securities, by set-off or otherwise, to which the holders of the Subordinated
Debt would be entitled but for the provisions of this Section 8 shall be paid by the liquidating
trustee or agent or other Person making such payment or distribution, whether a trustee in
bankruptcy, a receiver or liquidating trustee or otherwise, directly to the holders of Senior Debt
or their agents or representatives or to the trustee or trustees under any indenture under which
any instruments evidencing any of such Senior Debt may have been issued, ratably according to the
aggregate amounts remaining unpaid on account of the principal of, interest on and any premium or
other amounts payable with respect to the Senior Debt held or represented by each such holder, to
the extent necessary to make payment in full of all Senior Debt remaining unpaid, after giving
effect to any concurrent payment or distribution to the holders of the Senior Debt.

          The consolidation of Borrower with, or the merger of Borrower into, another entity shall not
be deemed a dissolution, winding up, liquidation or reorganization of Borrower for the purposes of
this Subsection 8.3 if such other entity is organized in the United States and such entity, as a
part of such consolidation or merger, succeeds to Borrower’s property and business and assumes
Borrower’s obligations (including the Senior Debt and the Subordinated Debt).

          8.4 Payment Held in Trust. All payments or distributions by Borrower upon or with respect to the Subordinated
Debt which are received by the holders thereof in violation of or contrary to the provisions of
Subsections 8.2 or 8.3 above shall be received in trust for the benefit of the holders of the
Senior Debt and shall be paid over upon demand to such holders in the same form as so received
(with all necessary endorsements) to be applied to the payment of the Senior Debt.

          8.5 Subrogation. Upon receipt by the holders of the Senior Debt of amounts sufficient
to pay all Senior Debt in full, to the extent any amounts which are otherwise payable with respect
to the Subordinated Debt but for the provisions of this Section 8 have been paid over to the
holders of the Senior Debt, the holders of the Subordinated Debt shall be subrogated to the rights
of the holders of Senior Debt to receive payments or distributions of cash, property or securities
of Borrower applicable to Senior Debt until the Subordinated Debt is paid in full, and no such
payments or distributions to the holders of the Senior Debt of cash, property or securities
otherwise distributable to the holders of Subordinated Debt shall, as between Borrower, its
creditors (other than the holders of Senior Debt) and the holders of the

8

 

Subordinated Debt, be
deemed to be payment by Borrower to the holders of the Senior Debt. Upon any payment or
distribution of assets of Borrower referred to in this Section 8, the holders of the Subordinated
Debt shall be entitled to rely upon a certificate of the liquidating trustee or agent or other
Person making any distribution to the holders of the Subordinated Debt for the purpose of
ascertaining the Persons entitled to participate in such distribution, the holders of Senior Debt
and other indebtedness of Borrower, the amount thereof or payable thereon, the amount or amounts
paid or distributed thereon and all other facts pertinent thereto or to this Section 8. The
provisions of this Section 8 shall continue to be effective or be reinstated, as the case may be,
if at any time any payment of any of the Senior Debt is rescinded or must otherwise be returned by
the holders of the Senior Debt for any reason whatsoever (including, without limitation, the
insolvency, bankruptcy or reorganization of Borrower) all as though such payment had not been made.
Subject to the foregoing, the subordination provisions in this Section 8 shall terminate when all
the Senior Debt has been indefeasibly and irrevocably paid in full.

          8.6 Rights Not Subordinated. The provisions of this Section 8 are for the purpose of
defining the relative rights of the holders of Senior Debt on the one hand and the holders of
Subordinated Debt on the other hand, and nothing herein shall impair (as between Borrower and the
holders of the Subordinated Debt) Borrower’s obligation to the holders of the Subordinated Debt to
pay to such holders the full amount of the Subordinated Debt in accordance with the terms of this
Note. No provision of this Section 8 shall be construed to prevent the holders of the Subordinated
Debt from exercising all rights and remedies available under this Note or under applicable law upon
the occurrence of an Default or otherwise, subject to the rights of the holders of the Senior Debt
as set forth above to receive payments otherwise payable to the holders of the Subordinated Debt,
and no provision of this Section 8 shall be deemed to subordinate, to any extent, any claim or
right of any holder of the Subordinated Debt to any claim against Borrower by any creditor or any
other Person except to the extent expressly provided herein.

          8.7 Concurrent Maturity Dates. Notwithstanding anything to the contrary herein, in the event that (a) the Required
Repayment Date occurs on the Scheduled Maturity Date and (b) any portion of the Convertible Notes
Debt remains unpaid as of the Scheduled Maturity Date, the holders of all Convertible Notes Debt
shall be entitled to receive payment in full of the principal thereof, the interest due thereon and
any premium or other payment obligation with respect thereto before the holders of the Subordinated
Debt are entitled to receive any payment upon the Subordinated Debt.

          8.8 Amendment. The provisions of this Section 8 may not be amended or modified
without the written consent of the holders of all then outstanding Senior Debt.

     9. Representations and Warranties. Borrower hereby represents and warrants to Lender
that:

          9.1 Organization and Qualification. Borrower is duly incorporated, validly existing
and in good standing under the laws of the State of Delaware, with full corporate power and
authority to conduct its business as currently conducted as disclosed in the reports, schedules,
forms, statements and other documents required to be filed by it with the SEC since January 1,
2008, pursuant to the reporting requirements of the Exchange Act. Borrower is duly

9

 

qualified to do
business and is in good standing in every jurisdiction in which the nature of the business
conducted by it or property owned by it makes such qualification necessary, except where the
failure to be so qualified or in good standing, as the case may be, would not reasonably be
expected to have a Material Adverse Effect.

          9.2 Authorization; Enforcement. Borrower has all requisite corporate power and
authority to enter into and to perform its obligations under this Note and to consummate the
transactions contemplated hereby. The execution, delivery and performance of this Note by Borrower
has been duly authorized by Borrower’s Board of Directors. This Note has been duly executed by
Borrower and constitutes a legal, valid and binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of
creditors’ rights generally and by general equitable principles (whether enforcement is sought by
proceedings in equity or at law).

          9.3 No Conflicts; Government Consents and Permits.

               (a) The execution, delivery and performance of this Note by Borrower and the consummation by
Borrower of the transactions contemplated hereby will not (i) conflict with or result in a
violation of any provision of its certificate of incorporation or bylaws, (ii)
violate or conflict with, or result in a breach of any provision of, or constitute a default
under, any Material Agreement (as defined in the Purchase Agreement) to which Borrower is a party
(including, without limitation, any of the Senior Debt Documents) or (iii) result in a violation of
any law, rule, regulation, order, judgment or decree (including United States federal and state
securities laws and regulations and regulations of any self-regulatory organizations to which
Borrower or its securities are subject) applicable to Borrower, except in the case of clauses (ii)
and (iii) only, for such conflicts, breaches, defaults and violations as would not reasonably be
expected to have a Material Adverse Effect.

               (b) Borrower is not required to obtain any consent, authorization or order of, or make any
filing or registration with, any court or governmental agency or any regulatory or self regulatory
agency in order for it to execute, deliver or perform any of its obligations under this Note in
accordance with the terms hereof other than such as have been made or obtained.

     10. No Additional Indebtedness. So long as this Note is outstanding, Borrower shall
not, and Borrower shall not permit any of its subsidiaries to, directly or indirectly, incur or
guarantee, assume or suffer to exist any Indebtedness that would rank senior or pari passu to the
Note, other than the Senior Debt, Indebtedness existing on the date hereof and Permitted
Indebtedness.

     11. Loss, Theft, Destruction or Mutilation of Note. In the event of the loss, theft
or destruction of this Note, upon Borrower’s receipt of a reasonably satisfactory indemnification
agreement executed in favor of Borrower by Lender, or in the event of the mutilation of this Note,
upon Lender’s surrender to Borrower of the mutilated Note, Borrower shall execute and deliver to
Lender a new promissory note in form and content identical to this Note in replacement of the lost,
stolen, destroyed or mutilated Note.

10

 

     12. Notices. Any notice pursuant to this Note shall be given in writing by (a)
personal delivery, (b) reputable overnight delivery service with proof of delivery, (c) United
States Mail, postage prepaid, registered or certified mail, return receipt requested, or (d)
legible facsimile transmission, sent to the intended addressee at the address set forth below, or
to such other address or to the attention of such other Person as the addressee shall have
designated by written notice sent in accordance herewith. Any notice so given shall be deemed to
have been given upon receipt or refusal to accept delivery, or, in the case of facsimile
transmission, as of the date of the facsimile transmission provided that an original of such
facsimile is also sent to the intended addressee by means described in clauses (a), (b) or (c)
above. Unless changed in accordance with the preceding sentence, the addresses for notices given
pursuant to this Note shall be as follows:

	 	 	 	 	 	 	 

	 

	 	If to Lender:
	 	Watson Pharmaceuticals, Inc.
	 

	 	 	 	 	 	311 Bonnie Circle
	 

	 	 	 	 	 	Corona, California 92880
	 

	 	 	 	 	 	Attention: General Counsel
	 

	 	 	 	 	 	Facsimile: 951.493.5817
	 
	 	 	 	 	 	 
	 	 	If to Borrower:	 	Columbia Laboratories, Inc.
	 

	 	 	 	 	 	354 Eisenhower Parkway
	 

	 	 	 	 	 	Plaza 1, Second Floor
	 

	 	 	 	 	 	Livingston, NJ 07039
	 

	 	 	 	 	 	Attention: General Counsel
	 

	 	 	 	 	 	Facsimile: 973.994.3001
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	with a copy to:
	 
	 	 	 	 	 	 
	 	 	 	 	Kaye Scholer LLP
	 

	 	 	 	 	 	425 Park Avenue
	 

	 	 	 	 	 	New York, New York 10022
	 

	 	 	 	 	 	Attention: Adam Golden, Esq. and Steven G. Canner, Esq.
	 

	 	 	 	 	 	Facsimile: 212.836.8689

     13. Time of Essence. Time is of the essence in the performance of each and every
provision hereof.

     14. Severability. If any provision hereof should be held unenforceable or void, then
such provision shall be deemed separable from the remaining provisions and shall in no way affect
the validity of this Note.

     15. Changes. This Note may not be changed orally, but only by an agreement in writing
and signed by the party against whom enforcement of any waiver, change, modification or discharge
is sought.

     16. Governing Law. This Note shall be governed by and construed in accordance with
the laws of the state of New York.

11

 

     17. Purpose. The proceeds of this Note are intended to be used by Borrower for
purposes of financing product development activities relating to Prochieve for the PTB Indication
(as defined in the Purchase Agreement) and for general corporate purposes.

     18. Successors and Assigns. The provisions of this Note shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and assigns, except that (i) Borrower may not assign or
otherwise transfer any of its rights or obligations hereunder without the prior written consent of
Lender and (ii) prior to the Required Repayment Date, Lender may not assign or otherwise transfer
any of its rights or obligations hereunder without the prior written consent of Borrower (other
than to a subsidiary of Lender that agrees to be bound by the terms hereof). Any attempted
assignment or transfer by Borrower or Lender in contravention of this Section 18 shall be null and
void.

[signature page follows]

12

 

     IN WITNESS WHEREOF, Borrower has executed this Note as of the date first written above.

	 	 	 	 	 
	 	BORROWER:

COLUMBIA LABORATORIES, INC., 

a Delaware corporation

 	 
	 	By:  	/s/ Frank C. Condella, Jr.
 	 
	 	Name:  	Frank C. Condella, Jr. 	 
	 	Title:  	President and CEO 	 
	 

	 	 	 	 	 
	ACCEPTED AND AGREED TO

on this 1st day of June, 2010

WATSON PHARMACEUTICALS, INC.

 	 	 
	By:  	/s/
David A. Buchen
 	 	 
	Name:  	David A. Buchen 	 	 
	Title:  	Senior Vice-President, General
Counsel & Secretary 	 	 
	 

13exv10w1

Exhibit 10.1

FIFTH AMENDMENT TO

EMPLOYMENT AGREEMENT

     This Fifth Amendment to Employment Agreement (this “Amendment”), dated as of June 1, 2010, is
made and entered into by and between ION Geophysical Corporation, a Delaware corporation
(hereinafter referred to as “Employer”), and Robert P. Peebler, an individual currently residing in
Harris County, Texas (hereinafter referred to as “Employee”).

WITNESSETH:

     WHEREAS, Employer and Employee entered into an Employment Agreement effective on March 31,
2003, and amended by that certain First Amendment to Employment Agreement dated September 6, 2006,
Second Amendment to Employment Agreement dated February 16, 2007, Third Amendment to Employment
Agreement dated August 21, 2007 and Fourth Amendment to Employment Agreement dated January 26, 2009
(as amended, the “Agreement”);

     WHEREAS, the parties desire to amend the Agreement as set forth below;

     NOW, THEREFORE, in consideration of the mutual promises contained herein and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer
and Employee agree as follows:

1. Section 2(c) of the Agreement is hereby amended to read in its entirety as follows:

     On June 1, 2010, Employee shall be entitled to receive a grant of 300,000
shares of restricted common stock of Employer. This restricted stock award will
provide for cliff vesting of all of the shares of restricted stock on the date that
is the earlier of:

	 	i.	 	June 1, 2013;
	 
	 	ii.	 	A “Change in Control” occurs (as
defined by Section 6 of this Agreement);
	 
	 	iii.	 	Employee’s termination of employment
due to the Disability (as defined in Section 5 of this
Agreement) or death of Employee;
	 
	 	iv.	 	Employee’s Retirement (as defined by
Employer’s Fifth Amended and Restated 2004 Long-Term Incentive
Plan (the “Plan”));
	 
	 	v.	 	Employee’s voluntary termination of employment
from Employer at any time after Employee’s successor is appointed; or
	 
	 	vi.	 	Employee’s employment is terminated (a) by
Employer for no reason or for any reason other than Cause, the death or
Disability of Employee, or the expiration of the Term, or (b) by
Employee for Good Reason.

 

 

In accordance with the terms of the Plan, any voluntary termination of employment
from Employer by Employee after Employee’s successor is appointed shall be treated
for all purposes under the Plan as a termination due to the Retirement of Employee.
The remaining terms and conditions of the restricted stock award will be governed by
the applicable restricted stock agreement and the terms and conditions of the Plan.

     2. Section 4 of the Agreement is hereby amended to read in its entirety as follows:

Employee’s employment with Employer will commence on March 31, 2003, and will expire
on December 31, 2012 (the “Term”), unless terminated earlier in accordance with
Section 5.

     3. Section 6(c) of the Agreement is hereby amended to read in its entirety as follows:

     (c) Upon termination of this Agreement due to the expiration of the Term,
Employee will continue to be employed by Employer as an employee at will. Upon
termination of Employee’s employment due to (i) Employee’s Retirement (as defined by
the Plan) or (ii) Employee’s voluntary termination of employment from the Company at
any time after Employee’s successor is appointed, Employee shall serve as a
non-employee consultant to the Board of Directors of Employer for a term of five
years. In consideration for such consulting services, Employer shall pay Employee a
consulting fee of $150,000 per year.

     4. The Agreement, as amended hereby, is in all respects ratified, approved and confirmed.

     5. This Amendment shall in all respects be governed by, and construed in accordance with, the
laws of the State of Texas, including all matters of construction, validity and performance.

     IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this
Amendment as of the date set forth above.

	 	 	 	 	 
	 	EMPLOYER:

ION GEOPHYSICAL CORPORATION

 	 
	 	By:  	/s/ James M. Lapeyre, Jr.
 	 
	 	 	Title: Chairman of the Board 	 
	 	 	 	 

2

 

	 	 	 	 	 

	 	 	 	 	 
	 	EMPLOYEE:

 	 
	 	/s/ Robert P. Peebler
 	 
	 	Robert P. Peebler 	 
	 	 	 
	 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]